|
WO2016063289A2
|
|
Pharmaceutical tablet compositions comprising rifaximin
|
|
WO2012131734A1
|
|
Topical composition for the treatment of vitiligo
|
|
WO2011013138A1
|
|
Stable multi- vitamin formulations
|
|
WO2011061748A1
|
|
Rifaximin premix
|
|
WO2010044093A1
|
|
Formulations containing rifaximin
|
|
EP1681050A1
|
|
Dispersible sustained release pharmaceutical compositions
|
|
WO2007060682A1
|
|
Effervescent granular formulations of antiretroviral drugs
|
|
WO2006097938A1
|
|
Stable liquid suspension formulation comprising tibolone and process for producing the same
|
|
GB0624498D0
|
|
Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
|
|
WO2005120517A1
|
|
Stable liquid suspension formulation comprising synthetic steroids and process for producing the same
|
|
AU2003230190A8
|
|
Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same
|
|
AU2003230191A1
|
|
Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
|
|
AU2003224419A1
|
|
Orally administrable pharmaceutical formulation
|
|
WO03101378A2
|
|
Pharmaceutical formulation in a drug delivery system and process for preparing the same
|
|
WO03032896A2
|
|
Dexibuprofen-containing soft gelatin capsules and process for preparing the same
|
|
BR0201762A
|
|
Mycophenolate mofetil tablets
|
